Application of propofol target controlled infusion and esmketamine in radical operation of thyroid cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046368

Enrollment

Unknown

Registered

2021-05-15

Start date

2021-05-15

Completion date

Unknown

Last updated

2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid cancer

Interventions

Esketamine low-dose group :Esketamine

High-dose esketamine group:High-dose esketamine

Control group:No

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Patients with thyroid cancer between 18 and 65 years old; 2. ASA score I-II grade; 3. The BMI value is in the range of 18.5-23.9; 4. TNM staging stages I-II; 5. No history of alcohol abuse; 6. Eliminate distant metastases.

Exclusion criteria

Exclusion criteria: 1. History of cardiovascular, endocrine and immune system diseases; 2. History of tumor radiotherapy and chemotherapy; 3. The application history of hormones and immunosuppressants; 4. A history of taking analgesics for a long time; 5. Recent history of infection and history of chronic infection; 6. Complications of important organs; 7. Patients who are allergic to this product and excipients; 8. Patients deemed unsuitable for participation by the researcher.

Design outcomes

Primary

Measure	Time frame
VAS score;	—

Countries

China

Contacts

Public ContactHuang Zeqing

Liaoning Cancer Hospital

huangzq0@163.com+86 18900917545

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026